Gemtesa and Pain in extremity - a phase IV clinical study of FDA data

Summary:

Pain in extremity is reported as a side effect among people who take Gemtesa (vibegron), especially for people who are female, 60+ old, also take Vitamin D3, and have Hypertonic bladder.

The phase IV clinical study analyzes which people have Pain in extremity when taking Gemtesa. It is created by eHealthMe based on reports of 2,622 people who have side effects when taking Gemtesa from the FDA, and is updated regularly.

What is Gemtesa?

Gemtesa has active ingredients of vibegron. eHealthMe is studying from 2,648 Gemtesa users. Check the latest studies of Gemtesa.

What is Pain in extremity?

Pain in extremity is found to be associated with 3,223 drugs and 4,298 conditions by eHealthMe. Check the latest studies of Pain in extremity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

2,622 people reported to have side effects when taking Gemtesa.
Among them, 15 people (0.57%) have Pain in extremity.

Among these 15 people:

What is the gender of people who have Pain in extremity when taking Gemtesa? *

female: 73.33 %
male: 26.67 %

What is the age of people who have Pain in extremity when taking Gemtesa? *

What are other drugs people take besides Gemtesa? *

What are other side effects people have besides Pain in extremity? *

Pain: 5 people, 33.33%
Back Pain: 5 people, 33.33%
Fatigue (feeling of tiredness): 4 people, 26.67%
Gait Disturbance: 3 people, 20.00%
Weakness: 3 people, 20.00%
Joint Pain: 3 people, 20.00%
Drug Ineffective: 3 people, 20.00%
Chest Pain: 3 people, 20.00%
Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 2 people, 13.33%
Fall: 2 people, 13.33%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 13.33%
Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 2 people, 13.33%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 13.33%
Multiple Myeloma (cancer of the plasma cells): 2 people, 13.33%
Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 2 people, 13.33%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 6.67%
Primary Immunodeficiency Syndrome: 1 person, 6.67%
Pain: 1 person, 6.67%
Osteoporosis (bones weak and more likely to break): 1 person, 6.67%
Immunodeficiency Common Variable: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Gemtesa and have Pain in extremity?

- Check whether Pain in extremity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gemtesa:

Gemtesa (2,648 reports)

Pain in extremity treatments and more:

Pain in extremity (376,792 reports)

Browse all side effects of Gemtesa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pain in extremity:

Pain in extremity (3,223 drugs)

Browse all the conditions that are associated with Pain in extremity:

Pain in extremity (4,298 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vibegron (the active ingredients of Gemtesa) and Gemtesa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.